banner
Dec 26, 2020
93 Views
0 0

Global Adalimumab Biosimilar Market- Industry Analysis and Forecast (2019-2027)

Written by

i am rahul

Global Adalimumab Biosimilar Market – Global Adalimumab Biosimilar Market was valued US$ XX Mn in 2019 and is expected to grow US$ XX Mn by 2027, at a CAGR of XX% during the forecast period.

Global Adalimumab Biosimilar Market

The report study has analyzed the revenue impact of the COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

A biosimilar is a type of biologic equivalent to that of pre-approved biologics. Adalimumab was the first fully human monoclonal antibody permitted by the U.S. Food and Drug Administration in December 2002. Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and many other diseases.

The growth factors like the increasing occurrence of arthritis among the global population and an increase in the number of skin disorders leading to a rise in demand for adalimumab. Also, the introduction of new biosimilars will lead to the decline in rates of the drugs in the global market, then leading to high demand in the market. This is expected to fuel the growth of the global adalimumab biosimilars market in the future.

The faster performance of digitalization between doctors and patients is expected to drive the market in the adalimumab biosimilar business. Also, emerging by capita earnings and thriving subsistence measures are expected to encourage the market. Some of the other factors motivating the business growth are as follows, many biopharmaceuticals conforming off-license over the succeeding years, emerging market for biosimilar medications because of their cost-effectiveness. However, remarkable expenses combined with the materials and shortage of skillful specialists to operate are a few factors that may hinder the growth in the adalimumab biosimilar market in the current future. Also, the factor like the high sensitivity towards temperature, absence of efficacy and safety, high manufacturing cost related to generic drugs are expected to limit the market growth during the forecast period (2020-2027).

The adalimumab biosimilar market is segmented by product and distribution channels. The product segment is further sub-segmented into Exemptia, Adalirel, Cipleumab, Others. The distribution channel is further sub-segmented into Hospitals Pharmacies, Retail Pharmacies, and Others.

Region-wise, North America is expected to hold the largest market share of the global adalimumab biosimilars market in 2019, thanks to the increasing occurrence of rheumatoid arthritis with the rise in the aged population. Europe is the second-largest market, because of a rise in the approvals of the new biosimilars, a rise in the aged population, high investment in the research and manufacturing of the new adalimumab biosimilars. From 2018, five new adalimumab biosimilars names as ABP501 (Amgevita), SB5 (Imraldi), GP2017 (Hyrimoz), FKB327 (Hulio), MSB11022 (Idacio) have been permitted in Europe. ABP501 was the first European Commission permitted adalimumab biosimilar. It is sold by Amgen under the brand name AMGEVITA. These new biosimilars are expected to drive the growth of the global adalimumab biosimilars market in the forecast period.

The objective of the report is to present a comprehensive analysis of the Global Adalimumab Biosimilar Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Adalimumab Biosimilar Market dynamics, structure by analyzing the market segments and project the Global Adalimumab Biosimilar Market size. Clear representation of competitive analysis of key players By Product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Adalimumab Biosimilar Market make the report investor’s guide.

visit at-https://www.maximizemarketresearch.com/market-report/global-adalimumab-biosimilar-market/79900/

Scope of the Global Adalimumab Biosimilar Market

Global Adalimumab Biosimilar Market, By Product

• Exemptia
• Adalirel
• Cipleumab
• Others
Global Adalimumab Biosimilar Market, By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Others
Global Adalimumab Biosimilar Market, By Region

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• South America
Key players operating in the Global Adalimumab Biosimilar Market

• Alfred E. Tiefenbacher (GmbH & Co. KG)
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Glenmark
• Zydus Cadila
• Torrent Pharmaceuticals Ltd.
• Reliance Life Sciences
• Emcure Pharmaceuticals Ltd
• Cipla Inc.
• Hetero
• Others

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:
Name: Vikas Godage
Organization: Maximize Market Research Pvt.Ltd.Pune
Email: [email protected]
Contact: +919607065656 / +919607195908
Website:www.maximizemarketresearch.com

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Article Categories:
Business
banner

Comments are closed.